Navigation Links
Engineered immune cells produce complete response in child with an aggressive pediatric leukemia
Date:12/9/2012

By reprogramming a 7-year-old girl's own immune cells to attack an aggressive form of childhood leukemia, a pediatric oncologist has achieved a complete response in his patient, who faced grim prospects when she relapsed after conventional treatment. The innovative experimental therapy used bioengineered T cells, custom-designed to multiply rapidly in the patient, and then destroy leukemia cells. After the treatment, the child's doctors found that she had no evidence of cancer.

Pediatric oncologist Stephan A. Grupp, M.D., Ph.D., of The Children's Hospital of Philadelphia, and colleagues from the University of Pennsylvania presented updated results of the clinical trial involving these engineered cells at the American Society of Hematology (ASH) annual meeting today in Atlanta. Grupp is the director of Translational Research for the Center for Childhood Cancer Research at The Children's Hospital of Philadelphia, and a professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania.

Grupp's research builds on his ongoing collaboration with Penn scientists who originally developed the modified T cells as a treatment for B-cell leukemias. The Penn team reported on early results of a trial using this cell therapy in adult chronic lymphocytic leukemia (CLL) patients in August of 2011. Carl H. June, M.D., of the Perelman School of Medicine at the University of Pennsylvania, leads this research group, which along with Grupp's work, is presenting new data at the ASH meeting showing that nine of 12 patients with advanced leukemias in the clinical trial, including two children, responded to treatment with CTL019 cells.

One of the nine responding patients is the 7-year-old with acute lymphoblastic leukemia (ALL). Grupp and Penn colleagues adapted the treatment to combat ALL, the most common childhood leukemia, and also the most common childhood cancer. Although physicians can cure roughly 85 percent of ALL cases, the
'/>"/>

Contact: Rachel Salis-Silverman
Salis@email.chop.edu
267-970-3685
Children's Hospital of Philadelphia
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Leukemia patients remain in remission more than 2 years after engineered T cell therapy
2. Bioengineered marine algae expands environments where biofuels can be produced
3. Soft Robotics: A groundbreaking new journal on engineered soft devices that Interact with Living Systems
4. Engineered bacteria can make the ultimate sacrifice
5. Ecologist: Genetically engineered algae for biofuel pose potential risks that should be studied
6. Success of engineered tissue depends on where its grown
7. Lab-engineered kidney project reaches early milestone
8. Engineered robot interacts with live fish
9. Engineered microvessels provide a 3-D test bed for human diseases
10. New research reveals challenges in genetically engineered crop regulatory process
11. Ultrasound idea: Prototype NIST/CU bioreactor evaluates engineered tissue while creating it
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2015)... , Feb. 13, 2015 ACT Genomics ... that aims to transform cancer genomic information into ... the company has raised US$ 8 million in the ... in Taipei, Taiwan , ACT ... ACTOnco™. With the aim to implement next generation ...
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
(Date:2/5/2015)... PARK, North Carolina , 5. Februar ... 35. Jahr als spezialisiertes Logistikunternehmen und hat ... als einzige klinische Logistikfirma (Clinical Logistics Organization ... Kernbotschaft der neuen Kampagne lautet First ... Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
... AURORA, Colo. (Dec. 9, 2013) A new study shows ... concussions than those closer to sea-level, a phenomenon attributed to ... tightly in the skull. "This is the first time ... Comstock, PhD, associate professor of epidemiology at the Colorado School ...
... Liver (EASL) today publishes their revised Clinical Practice Guidelines ... (HCV) (1). The EASL guidelines, which supersede the ... physicians and other healthcare providers optimise their management of ... estimated that approximately 160 million individuals, i.e. 2.35% of ...
... of tumours in over one per cent of all cancer ... has been broadly linked to cancer development. The team ... activated that increases tumour growth. Drugs that inhibit the biological ... in development thus highlighting a potential new targeted therapy for ...
Cached Biology News:Study shows first link between altitude and concussion 2EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus 2EASL publishes revised clinical practice guidelines to optimise the management of hepatitis C virus 3Gene promotes 1 in 100 of tumors 2
(Date:2/27/2015)... San Francisco, CA (PRWEB) February 27, 2015 ... is joining forces on February 28 with patients and ... to raise awareness for Rare Disease Day®. Rare ... rare diseases and calling attention to the special challenges ... community around them. , “Cytokinetics is proud to stand ...
(Date:2/26/2015)... Feb. 26, 2015  23andMe, the leading personal genetics ... as Privacy Officer and Corporate Counsel. Black brings ... laws as well as health care regulations. As a ... be responsible for reviewing, updating and enhancing the company,s ... and abroad. She joined the company January 5, 2015 ...
(Date:2/26/2015)... , Feb. 26, 2015 DuPont Executive ... priorities driven by key research advancements and product launches ... today,s Bank of America Merrill Lynch 2015 Global Agriculture ... challenge of building grain supplies the last two years, ... at the pace of the last decade, when demand ...
(Date:2/26/2015)... -- BioEnterprise today announced that Northeast Ohio ... billion in growth funding during the past 13 years.  ... state – including the Ohio Third Frontier - and ... been raised in the past five years. ... BioEnterprise Midwest Healthcare Growth Capital  Report.   ...
Breaking Biology Technology:Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 623andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4
... ARLINGTON, Va., July 13 The Generic Pharmaceutical Association ... Kathleen Jaeger on the Senate HELP Committee,s vote on biogenerics legislation. ... disappointed that the Committee action could result in patients having little ... in the House to ensure that a true balance is achieved ...
... 13, 2009) Whitehead Institute scientists have developed a ... target diseases that until now have stymied drug developers, ... yeast to synthesize and screen the molecules, cutting target ... weeks. The current drug discovery process ...
... ERT (Nasdaq: ERES ), a leading provider of ... medical device, and related industries, announced today that it will release ... 2009 after the market closes. After the release, the Company will ... , For the conference call, interested ...
Cached Biology Technology:GPhA Calls Senate HELP Committee Action Disappointing for Countless Patients 2New method may accelerate drug discovery for difficult diseases like Parkinson's 2New method may accelerate drug discovery for difficult diseases like Parkinson's 3New method may accelerate drug discovery for difficult diseases like Parkinson's 4ERT to Announce 2009 Second Quarter Results on July 30, 2009 2
... glycerol stocks contained in standard 96-well microtiter ... with approximately 5,000 clones per plate. After ... well, the corresponding subplate is screened with ... positive well(s). Cells from a positive well ...
... designed for flexibility and routine operation. With ... lens, true hyperbolic quadrupole and high-speed simultaneous ... range of sample types and applications. New ... standard Agilents unique ShieldTorch System, which enables ...
... is a fully automated microplate luminescence ... widest possible range of applications based ... assays luciferase, -galactosidase, gene activities with ... Luminescent Immunoassays Cell-based assays ...
... depleted sera are specifically depleted of a ... the depleted protein, the alternative and classical ... therefore ideal for the detection and quantitation ... have been used to assess complement activation ...
Biology Products: